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DegradationGCK-MODY, dominantly inherited mild fasting hyperglycemia, has been associated with >600 different mu-
tations in the glucokinase (GK)-encoding gene (GCK). When expressed as recombinant pancreatic proteins,
some mutations result in enzymes with normal/near-normal catalytic properties. The molecular mecha-
nism(s) of GCK-MODY due to these mutations has remained elusive. Here, we aimed to explore the molecular
mechanisms for two such catalytically ‘normal’ GCK mutations (S263P and G264S) in the F260-L270 loop of
GK. When stably overexpressed in HEK293 cells and MIN6 β-cells, the S263P- and G264S-encoded mutations
generated misfolded proteins with an increased rate of degradation (S263P>G264S) by the protein quality
control machinery, and a propensity to self-associate (G264S>S263P) and form dimers (SDS resistant) and
aggregates (partly Triton X-100 insoluble), as determined by pulse-chase experiments and subcellular frac-
tionation. Thus, the GCK-MODY mutations S263P and G264S lead to protein misfolding causing destabiliza-
tion, cellular dimerization/aggregation and enhanced rate of degradation. In silico predicted conformational
changes of the F260-L270 loop structure are considered to mediate the dimerization of both mutant proteins
by a domain swapping mechanism. Thus, similar properties may represent the molecular mechanisms for ad-
ditional unexplained GCK-MODY mutations, and may also contribute to the disease mechanism in other pre-
viously characterized GCK-MODY inactivating mutations.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The enzyme glucokinase (GK), also denoted hexokinase IV
(EC 2.7.1.1), is an important factor in the regulation of blood glucose,
by acting as the ‘glucose sensor’ of the pancreatic β-cells. GK catalyzes
the phosphorylation of α-D-glucose (Glc) to form glucose-6-phosphate,
the entry point into glycolysis. The enzyme is expressed in hepatocytes
[1], pancreatic β-cells [2,3], as well as in the brain and endocrine cellsglucokinase regulatory protein;
cells; hGK, human glucokinase;
etes of the young; PDB, protein
ticulocyte lysate; TEV protease,
ystem
edicine, University of Bergen,
55975159.
rights reserved.in the gut [4]. GK is activated by glucose binding, which in the hepato-
cytes (GK isoform 2) results in stimulation of glucose uptake, glycolysis
and glycogen synthesis, and in the β-cells (GK isoform 1) mediates
glucose-stimulated insulin secretion (GSIS) [5,6].
A complex network of protein–protein interactions has been
reported for the posttranslational regulation of GK in the pancreatic
β-cell and liver hepatocytes [7–10]. In hepatocytes, GK catalytic activity
and cytoplasm↔nucleus transport is controlledby theGK regulatory pro-
tein (GKRP) [7,8]. The bifunctional enzyme 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase (PFK-2/FBPase-2), expressed in both pancre-
atic β-cells and liver, plays a role in GK activation [9,10]. Moreover, post-
translational modiﬁcations like S-nitrosylation [11] and ubiquitination
[12] have also been associated with GK regulation.
The key role of GK in glucose homeostasis is illustrated by its three
associated forms of ‘glucokinase disease’ caused by different muta-
tions in its encoding gene (GCK). Heterozygous mutations that de-
crease GK enzyme activity result in one of the most common forms
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or MODY2 (MODY2; MIM#125851), and is characterized by mild
fasting hyperglycemia [13,14]. Homozygous or compound heterozy-
gous inactivating mutations result in the more severe permanent
neonatal diabetes mellitus [15]. The opposite phenotype exists in per-
sistent hyperinsulinemic hypoglycemia of infancy (PHHI) due to mu-
tations that increase GK enzyme activity [16]. Of the >600 GCK
mutations identiﬁed to date, around 80 have been functionally char-
acterized [17], most of them as recombinant pancreatic GST fusion
proteins. The majority of these mutations are associated with altered
enzyme kinetic parameters and overall phosphorylating capacity
[17], mainly by affecting the afﬁnity for its substrates Glc and ATP
[18,19]. In some cases, the GCK-MODY mutations have near‐normal
enzyme kinetics, or even a mild increase in afﬁnity for Glc, and
show normal regulation by allosteric inhibitor/activator molecules
(GKRP and GKAs) [20–23]. Thus, the molecular mechanism leading
to their diabetes remains unexplained. For some mutations, a cellular
instability or defect in S-nitrosylation has been indicated [24–26].
In the present work, we have studied two GCK-MODY mutations
causing amino acid changes S263P and G264S in the F260-L270 loop
structure of pancreatic humanGK (hGK), and reported to result inGK en-
zymeswith normal or near‐normal kinetic parameters, at least as GST fu-
sion proteins [21,27]. We have reinvestigated their steady-state kinetic
properties using both GST-tagged and tag-free proteins at two tempera-
tures (30 and 37 °C). Also, we have studied their conformational, folding
and stability properties by (i) in vitro susceptibility to limited proteolysis,
(ii) stability in human embryonic kidney (HEK293) cells and mouse
insulinoma (MIN6) β-cells in pulse-chase experiments, and (iii) in silico
protein conformational changes in the loop region.
2. Materials and methods
2.1. Materials
We purchased factor Xa from Protein Engineering Technology ApS
(Aarhus, Denmark), and trypsin and soybean trypsin inhibitor from
Sigma-Aldrich (St. Louis, MO, USA). We obtained TnT® T7 Quick
Coupled Transcription/Translation System, MagneHis Protein Puriﬁ-
cation System and FastBreak lysis buffer from Promega (Madison,
WI, USA). Proteasomal inhibitor (MG132) and Ub aldehyde were
from Biomol (Cambridge, MA, USA). Protease inhibitor cocktail was
fromF.Hoffmann-La Roche (Mannheim,Germany) and the bicinchoninic
acid (BCA) protein assay kit from Pierce (Rockford, IL, USA). We bought
the lysosomal protease inhibitor leupeptin from Sigma-Aldrich
(St. Louis, MO, USA). SDS- and native-PAGE gels and buffers, and Hank's
balanced salt solution were from Invitrogen (Grand Island, NY, USA).
Glutathione Sepharose 4B was obtained from GE Healthcare (Bucking-
hamshire, UK). Antibody (Ab) anti-GK (h-88) was from Santa Cruz Bio-
technology (Santa Cruz, CA, USA) and anti-V5 from Invitrogen. We
obtained anti β-actin from Abcam (Cambridge, UK).
2.2. Expression and puriﬁcation of recombinant hGK
We expressed and puriﬁed wild-type (WT) and mutant pancreatic
hGK in pGEX-3X vector as glutathione-S-transferase (GST) fusion
proteins [28]. The recovery of puriﬁed protein was 1.6 mg of soluble
protein per liter of culture for WT hGK and 1.0–1.5 mg for the mutant
proteins. Puriﬁed proteins were high-speed centrifuged (267,000g,
15 min, 4 °C) to remove any aggregates, then concentrated, aliquoted,
and stored in liquid nitrogen in the absence of glucose. We determined
protein concentrations usingA280 (1mg⋅ml−1⋅cm−1) of 1.05 (GST fusion
protein) [28]. The recombinant proteinswere isolated to a purity of >95%
(SDS/PAGE) with an expected molecular mass of 76 kDa, as previously
described for GST-tagged WT hGK [12]. To remove the GST partner the
proteins were cleaved for 3 h at 4 °C by factor Xa protease, using a prote-
ase to substrate ratio of 1:25 (by mass).2.3. Steady-state kinetics
We determined the steady-state kinetic properties of both GST-
and non-tagged (cleaved) WT and mutant hGK proteins with glucose
(1–60 mM; ATP 5 mM) or ATP (0.025–5 mM; saturating amount of
glucose) as the variable substrate. GK activity was measured, after
pre‐equilibration with glucose, by a glucose 6-phosphate dehydroge-
nase (G6PDH)-coupled assay as described previously [28]. Kinetic pa-
rameters were calculated by nonlinear regression analysis using the
Hill equation. The catalytic activity (kcat) was determined for the
total enzyme pool (monomer and dimer; see Fig. 6H and I). We tested
a minimum of three different protein preparations.
2.4. Limited proteolysis by trypsin
We subjected non-taggedWT andmutant pancreatic hGK proteins to
limited proteolysis by trypsin at a hGK to trypsin ratio of 500:1 (bymass).
Proteolysis of 30 μghGKwas performed at 25 °C in a 100 μl reactionmix-
ture containing 20 mM Hepes (pH 7.0), 50 mM NaCl, 2 mM DTT, and in
the absence/presence of 40 mMglucose. Over time (0–30 min), the reac-
tions were stopped by adding soybean trypsin inhibitor, using a protease
to inhibitor ratio of 1:1.5 (by mass). We analyzed samples (4.5 μg) by
SDS/PAGE after denaturation at 56 °C for 15 min. Full-length hGK was
quantiﬁed by densitometric analysis using the Quantity One 1-D analysis
software (Systat Software, San Jose, CA, USA), and the data were plotted
using the Sigma Plot Software version 11.0 (Systat Software).
2.5. Degradation of hGK in an in vitro reticulocyte lysate system
We assessed the degradation of newly synthesized and ubiquitinated
[35S]Met‐labeledWT andmutant pancreatic hGK proteins in the in vitro
TnT® T7 Quick Coupled Transcription/Translation System as described
[12]. Thus, co-translational hGK degradation was measured after
30 min at 30 °C in the absence/presence of 100 μmol/l proteasomal
inhibitor (MG132) and 2 μmol/l Ub aldehyde. Samples were dena-
tured (56 °C, 15 min) and analyzed by SDS/PAGE. We quantiﬁed
total hGK by densitometric analysis using the Image Gauge v4.0
software (Fuji Film, Tokyo, Japan).
2.6. Assay of GK activity in transfected HEK293 cell lysate
We measured the activity of hGK in cytosolic fractions from early
passages (bF4) of stably transfected HEK293 cells (Fig. S1 – Supple-
mentary data) (MIN6 cells express GK and thus unsuitable for study-
ing the activity of transfected mutants). Cells (1×107) were washed,
harvested and pelleted by centrifugation (1372g, 5 min, 4 °C). We
resuspended cell pellets in ice-cold buffer containing 25 mM Hepes,
2.5 mM MgCl2, 25 mM KCl (pH 7.4), 1× protease inhibitor cocktail,
and homogenized the cells by 35 passages through a ball-bearing cell
cracker (EMBL, Heidelberg, Germany)with a clearance of 0.01 mm. Col-
lected lysates were cleared by centrifugation (267,000g, 15 min, 4 °C)
and GK-speciﬁc activity was measured at 30 °C in 100 μg of total pro-
tein as described under steady-state kinetics (Section 2.3). The back-
ground high-afﬁnity hexokinase activity was measured at 0.5 mM
glucose and subtracted from the GK activity measured at 1–60 mM
glucose.
2.7. Metabolic labeling and pulse-chase of hGK in HEK293 cells and MIN6
β-cells
HEK293 and MIN6 cells (3.5×105) stably expressing V5-His‐tagged
pancreatic hGK were rinsed (PBS), followed by 1 h incubation in Met/
Cys and serum free DMEM medium. Cells were then supplemented
with 5 μCi/ml of [35S]Met/[35S]Cys for 30 min (pulse), rinsed, and fur-
ther incubated in DMEM medium containing an excess (50×) of cold
Met and Cys (chase). We collected the cells at various time points. To
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somal protease inhibitor (leupeptin) on the rate of hGK degradation,
cells were treated with 10 μmol/l MG132 (DMSO in the control) and
100 μg/ml leupeptin (ddH2O in the control).
2.8. Native-PAGE electrophoresis
Stably transfected HEK293 and MIN6 cells were metabolically la-
beled with [35S]Met/[35S]Cys for 30 min and chased for 2 h as de-
scribed in Section 2.7. We washed and lysed cells in 1× FastBreak
lysis buffer (MagneHis kit) containing additional 40 mM imidazole,
500 mM NaCl and protease inhibitors. His-tagged hGK soluble forms
were isolated using the MagneHis Protein Puriﬁcation System ac-
cording to the manufacturer's protocol. We eluted bound proteins
by 500 mM imidazole/100 mM Hepes buffer (pH 7.5) and cleared
samples by high-speed centrifugation (417,200g, 1 h, 4 °C). The su-
pernatants were analyzed by native-PAGE (Novex 3–12% Bis–Tris
Gel) by running at 150 V for 1 h in dark blue, then at 200 V for 1 h
in light blue cathode buffers. The gels were ﬁxed, dried and labeled
bands detected by autoradiography. Pellets containing membrane-
associated hGK were resuspended in a SDS-containing buffer, dena-
tured (56 °C, 15 min) and analyzed by SDS/PAGE and immunoblot
analysis. Recombinant puriﬁed proteins were similarly analyzed by
native-PAGE. Gels were Coomassie stained or immunoblotted and
bands corresponding to monomeric/dimeric forms were quantitated
by densitometric analysis.
2.9. Determination of Triton X-100 soluble and Triton X-100 insoluble
mutant hGK
We washed and harvested 4×107 MIN6 cells, stably expressing
the G264S mutant, in Hank's balanced salt solution, pelleted cells byGlucose (mM)
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Fig. 1. Steady-state kinetic properties of recombinant WT and mutant pancreatic hGK with Glc
and tag-free enzyme (B and D) asmeasured spectrophotometrically at 30 °C (A and B) and 37
tion. The steady-state kinetic constants are summarized in Table 1.centrifugation (300g, 5 min), and resuspended in washing solution
(30 mM KCl, 140 mM NaCl, 10 mM EDTA, 25 mM Tris–HCl (pH 7.4)).
After repeating centrifugation (300g, 5 min), pelleted cells were
resuspended in ice-cold homogenization medium (HS) (130 mM KCl,
25 mM NaCl, 1 mM EGTA, 25 mM Tris–HCl (pH 7.4)), supplemented
with protease inhibitors, and lysed/homogenized by 35 passages through
a cell cracker (see Section 2.6). Cell breakage was monitored by phase-
contrast optics [29]. After centrifugation (600g, 10 min, 4 °C), we re-
moved the post‐nuclear supernatant (PNS) fraction and recentrifuged
(3000g, 10 min, 4 °C) the sample to pellet heavy mitochondria and lyso-
somes [30]. The supernatant and the pellet (resuspended in HS) fractions
were treated with 1% (w/v) Triton X‐100 for 30 min and centrifuged
(100,000g, 1 h, 4 °C). The supernatantwas referred to as TritonX-100 sol-
uble protein. We solubilized the pellet by sonication in 5 M guanidine
chloride, 50 mM Tris (pH 8.0), including protease inhibitors, incubated
overnight at room temperature, and centrifuged (13,000g, 20 min).
Samples were diluted 10-fold to reduce the concentration of denaturant.
Both supernatant and pellet fractions were denatured (56 °C, 15 min)
before analyzed by SDS/PAGE and immunoblotting.2.10. CD spectroscopy
WT and G264S hGK proteins were isolated from the GST-tag as
previously described [28]. The isolated proteins were further diluted
in a sodium phosphate buffer (pH 7.2) with 5 mM DTT to a ﬁnal con-
centration of 10 μM. The circular dichroism (CD) was recorded on a
Jasco J-810 spectropolarimeter. Thermal unfolding (15–90 °C)
was determined by following the change in ellipticity at 222 nm
(light path 1 mm) at a constant heating rate of 40 °C h−1. Using
the ﬁrst derivative of the smoothed curve, the midpoint of the
transition (Tm) was determined. The spectra data were plotted
using Sigma Plot Software version 11.0.60
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as the variable substrate. (A–D) The activity of 0.5 μg recombinant GST-tagged (A and C)
°C (C and D). The data were analyzed by nonlinear regression analysis using the Hill equa-
0 5 10 15 20 25 300 5 10 15 20 25 30
0
20
40
60
80
100 + Glc
WT 
Time (min)
S263P
Time (min)
0 5 10 15 20
0
100
G264S
A
%
 fu
ll-
le
ng
th
 h
G
K 
re
m
ai
ni
ng
B
C D
0.5
1.0
1.5
2.0
2.5
0
***
*
*
Time (min)
3025
100
80
60
40
20
0
80
60
40
20 MG132
-
-  Glc
+ Glc
-  Glc
+ Glc
-  Glc
%
 fu
ll-
le
ng
th
 h
G
K 
re
m
ai
ni
ng
Ex
pr
es
si
on
 (f
old
 ch
an
ge
)
%
 fu
ll-
le
ng
th
 h
G
K 
re
m
ai
ni
ng
Fig. 2. Probingprotein conformations by limited proteolysiswith trypsin and stability. (A–C)
Time course for the limited proteolysis of WT and mutant forms by trypsin at 25 °C in the
absence (white circles) and presence (black circles) of 40 mmol/l glucose. Protein (4.5 μg)
was removed at various time points, denatured and analyzed by SDS/PAGE (10%), followed
byCoomassie blue staining. Full-length proteinwas quantiﬁed bydensitometric analysis and
plotted as a function of time (A–C). Each time point represents the average of two individual
experiments (n=2). (D) In vitro stability of newly synthesized andpartly ubiquitinated hGK
forms, and the effect of the proteasome inhibitor MG132. His6-WT and -mutant forms were
expressed ([35S]Met-labeled) in an in vitro coupled transcription–translation RRL system
and their stability was measured after 30 min at 30 °C, in the absence (black columns)
and presence (white columns) of proteasome inhibitor (100 μmol/l MG132). Samples
were denatured and analyzed by SDS/PAGE (10%), autoradiography and densitometric
quantiﬁcation of total GK expression. Each column represents themean±SD of aminimum
of ﬁve independent experiments (n=5).
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See Supplementary materials and methods.
2.12. Statistical analysis
Data obtained from independent experiments (n≥3) are presented
asmean±SD and Student's t-test was conducted for statistical analysis
of quantitative data (pb0.05 was considered signiﬁcant).
2.13. Structural analyses
We computed the effect of themutations on protein thermodynam-
ic stability and protein conformation using the Medusa Force Field and
Modeling Suite [31,32]. The algorithm (http://eris.dokhlab.org) features
an all-atom force ﬁeld, a fast side chain packing algorithm and a back-
bone relaxation method. It models the backbone ﬂexibility, thereby
allowing for determination of the mutation-induced backbone confor-
mational changes.We generated structural images using PyMol version
1.1 [33]. The static solvent accessibility of the individual residues in the
two main conformational states was calculated using the CUPSAT
algorithm [34].
3. Results
3.1. Catalytic properties of WT hGK and GCK-MODY mutant enzymes
We subjected the recombinant WT and mutant pancreatic enzymes
to steady-state kinetic analyses at 30 and 37 °C as GST-tagged and
tag-free (cleaved) proteins (Fig. 1, Table 1). At both temperatures, the
S263P and G264S mutants demonstrated slightly reduced overall turn-
over rates (kcat) and increased [S]0.5 values for Glc compared to WT
hGK, consistent with previous reports [21,27]. Moreover, the Km value
for ATP was reduced for S263P (Table S1 – Supplementary data). For
this mutant, the reduced catalytic efﬁciency was most clearly observed
with the tag-free enzyme at 37 °C (Table 1).
3.2. Probing protein conformations by limited proteolysis with trypsin
Limited proteolysis is a commonly used tool for probing the fold-
ing state of a protein and characterization of mutational effects on
protein conformation and stability [35,36]. To evaluate the effect of
the GK residue changes S263P and G264S on the native folding of
the pancreatic protein, we compared the susceptibility of the WT
and mutant enzymes to limited proteolysis by trypsin. As seen from
Fig. 2 the S263P mutant protein demonstrated a higher susceptibility
to limited proteolysis shown by a more rapid cleavage than the WT
enzyme; the full-length protein was barely detectable after 10 min
both in the absence and presence of glucose (Fig. 2B). The G264STable 1
Steady-state kinetic parameters of WT and mutant hGK forms.
kcat (s−1) [S]0.5 (mM)
+ GST − GST + GST
Parameters (30 °C) WT 55±3 64±2 8.0±0.8
S263P 46±3 42±4 12±1.2
G264S 48±5 49±4 11±1.9
Parameters (37 ºC) WT 59±5 79±4 8.0±1.2
S263P 49±5 44±4 12±1.5
G264S 52±5 55±5 11±1.9
The catalytic activity was measured spectrophotometrically at 30 and 37 °C for GST-tagged
regression analysis and the Hill equation. The values were obtained from measurement
(0.025–5 mmol/l) and are representative of 3 different protein preparations.mutant demonstrated a similar time course for its proteolysis as
S263P in the absence of glucose (Fig. 2C), but was partly protected
by glucose.
3.3. Proteasomal degradation of recombinant hGK
We further assessed the stability of WT and mutant pancreatic hGK
enzymes by their susceptibility to proteasomal degradation [12]. [35S]
Met-labeled His6-hGK proteins were expressed in an in vitro coupled
transcription–translation system, and their degradation was followedkcat/[S]0.5 (mM−1s−1) (nH)
− GST + GST − GST + GST − GST
8.0±0.5 6.9±0.28 8.1±0.24 1.7±0.2 1.7±0.1
12±1.8 3.9±0.23 3.6±0.08 1.6±0.2 1.6±0.3
11±1.5 4.4±0.09 4.4±0.22 1.6±0.3 1.6±0.2
8.0±0.7 7.4±0.39 9.9±0.10 1.7±0.3 1.7±0.2
12±1.9 4.0±0.16 3.6±0.18 1.6±0.2 1.6±0.2
11±1.7 4.7±0.04 5.1±0.33 1.6±0.5 1.6±0.3
and tag-free (factor Xa cleaved) enzymes. Analyses were performed using nonlinear
s at various glucose concentrations (1–60 mmol/l) and various ATP concentrations
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quantiﬁcation of the protein samples revealed a ~2.1-fold increase in
the recovered WT enzyme in the presence of the proteasomal inhibitor
MG132.We observed a smaller effect of the inhibitor for the recovery of
the S263P (~1.2-fold increase) and G264S (~1.4-fold increase) mutant
proteins (Fig. 2D).
3.4. Degradation of hGK in stably transfected HEK293 cells andMIN6 β-cells
We then studied the stability/turnover of the S263P and G264S mu-
tant pancreatic proteins in stably transfected HEK293 (Fig. 3A and B)
and MIN6 cells (Fig. 3C and D). HEK293 cells were chosen as supple-
mentary cell line due to its high efﬁciency of transfection and protein
production. Cells were metabolically labelled for 30 min and chased
for a period of 0–12 h, followed by SDS/PAGE analysis and quantiﬁca-
tion of the immunoisolated proteins (Fig. 3A and C). The recovery of
full-length V5-tagged hGK (~53 kDa) decreased as a function of time,
and the apparent protein half-life (t1/2) was determined from
semi-logarithmic plots (Fig. 4) of the data (Fig. 3). WT hGK revealed a
biphasic time course for its degradation in both cell lines, with apparent
t1/2 values of 5.0 and ~13 h (Fig. 4A and B). By contrast, we observed a
monophasic time course for the recovery of the S263P and G264S mu-
tant proteins (~53 kDa), with apparent half-lives of 1.3 and 2.0 h for
S263P (Fig. 4C and D) and 4.9 and 5.3 h for G264S (Fig. 4E and F), in
HEK293 and MIN6 cells, respectively.
3.5. Effect of proteasomal and lysosomal inhibitors on the degradation of
hGK in stably transfected HEK293 cells and MIN6 β-cells
Considering the increased rate of degradation of the S263P and
G264S mutant proteins in HEK293 and MIN6 cells (Figs. 3 and 4), we
next investigated how the cellular proteolytic systems are involved in
their quality control and turnover. The degradation was studied by
pulse-chase experiments in stably transfected HEK293 and MIN6 cells G264S  
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Fig. 3. Time course of the cellular degradation of WT and mutant hGK forms. Stably transfect
Cys for 30 min and chased for 12 h. The recovery of WT, S263P and G264S mutant proteins w
and analyzed by SDS/PAGE (4–12%) and autoradiography (A and C). The bands of full-le
analysis and the data plotted as a function of chase time (B and D). The mean value of tri
each time point represents the mean±SD of triplicates examined on three independent dain the presence and absence (during the chase) of the proteasomal inhib-
itor MG132 (10 μmol/l) (Fig. 5A and B). After a 3 h chase, the recovery of
WT protein increased ~1.5-fold in HEK293 cells in the presence of inhib-
itor, while the S263P and G264S mutants increased ~1.2- and 1.3-fold,
respectively (Fig. 5A). We observed a similar increase in recovery of
WT and mutant proteins in stably transfected MIN6 cells (Fig. 5B) that
also correlatedwith our observations in the in vitro RRL system (Fig. 2D).
Due to the relatively long half-life of WT hGK in HEK293 and MIN6
cells (Fig. 4), we also investigated the contribution of the lysosomal
degradation system in the turnover of hGK in both cell lines. Here,
the chase period (0–3 h) was conducted in the presence or absence
of leupeptin, an inhibitor of lysosomal protein degradation (Fig. 5C
and D). The fold increase in the recovery of cellular mutant proteins
was signiﬁcantly (pb0.004) higher (S263P>G264S) than for WT
hGK in both HEK293 and MIN6 cells (Fig. 5C and D).
3.6. Intracellular dimerization and aggregation of the S263P and G264S
mutant proteins
We further compared the recovery of [35S]Met/[35S]Cys-labeled
WT and mutant enzymes, isolated from cell extracts (HEK293 and
MIN6 cells) (Fig. 6A and C), by native-PAGE analyses. Moreover, the
E. coli expressed and puriﬁed recombinant proteins were also ana-
lyzed and compared by native-PAGE electrophoresis (Fig. 6H and I).
In the cytosolic fractions from both cell lines, the immunoisolated
mutant proteins revealed radioactive bands with a relative mobility
corresponding to dimeric forms (~100 kDa), in addition to their mo-
nomeric forms of ~53 kDa (proteins with V5- and His-tag), which
were present at zero time and during chase time (Fig. 6A and C).
The relative content of the dimeric form represented 50–60% (both
mutants in HEK293), and 45–55% (S263P) and 30–35% (G264S) in
MIN6 cells (n=3). A similar high molecular mass (dimeric) band
(~100 kDa) was also detected by native-PAGE for both mutant re-
combinant enzymes (Fig. 6H and I), and estimated to represent ~5%Pr
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Fig. 4. Determination of the apparent cellular half-life of WT and mutant hGK forms. (A–F) Semi-logarithmic plot of the time course of the degradation of WT, S263P and G264S
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was observed for the S263P mutant in HEK293 (C) and MIN6 (D) cells, and the G264S mutant in HEK293 (E) and MIN6 (F) cells.
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These dimeric species were conﬁrmed to represent 55% (S263P) and
68% (G264S) GK peptide sequence by mass spectrophotometric
(LC-MS/MS) analyses (Orbitrap Velos Pro) (data not shown).Moreover,
dimeric and aggregated formswere also recovered for themutants from
the pellets of the PNS fractions, enriched in lysosomes and mitochon-
dria (Fig. 6B and D). These aggregated forms were most pronounced
in MIN6 cells (Fig. 6D), representing 70–80% (G264S>S263P) of total
immunoreactive protein. Only the monomeric form was detected for
the WT enzyme (Fig. 6A–D). Since the G264S mutant revealed the
highest propensity to form SDS-resistant dimers (and aggregates), we
further investigated the subcellular distribution of this mutant. Thema-
jority of the monomeric and dimeric species was recovered in the PNSfraction (Fig. 6E and F) and was mostly Triton X-100 soluble and partly
Triton X-100 insoluble, but soluble in guanidine chloride (Fig. 6E).
3.7. Catalytic activity of WT, S263P and G264S mutant enzymes stably
expressed in HEK 293 cells
To assess how the mutations affect the cellular GK catalytic activity,
we measured the activity of WT and mutant pancreatic enzymes at
30 °C in cytosolic fractions from stably transfected HEK293 cells (Fig. 7)
with glucose as the variable substrate (1–60 mM). Using equal amounts
of cellular monomeric GK protein, as determined by immunoblotting
(Fig. 7B), the homospeciﬁc activity of both mutants was lower than of
theWT enzyme (Fig. 7C), resembling to that determined for the puriﬁed
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the S263P cellular enzyme demonstrating a much lower afﬁnity for Glc.
3.8. Structural analysis
Recombinant hGK without a fusion partner is marginally stable
under physiological conditions. It has a low intrinsic thermal stability
with an apparent Tm of ~41 °C (Fig. 8A) and a propensity to aggregate
at Tp >40 °C [37,38]. Here we obtained a Tm of 36 °C for the G264S
mutant enzyme (Fig. 8B), ~5 °C below the WT, compatible with a
misfolded protein. Moreover, using an ANS ﬂuorescence binding
assay, a reduction in solvent exposed hydrophobic clusters in the mu-
tant vs. WT enzyme was demonstrated (Fig. S2).
In the closed, glucose-bound conformation of pancreatic hGK
(PDB i.d. 1v4s), the residues S263 and G264 are positioned in an
11-residue (F260–L270) loop structure (Fig. 9). In this loop, the
polypeptide chain folds back on itself, and its conformation is sta-
bilized by a network of hydrogen bonds (possibly involving three
water molecules) and hydrophobic interactions (residues F260,
L266 and L270), which project into the center of the loop, forming
a cluster of packed apolar side chains with very low static solvent
accessibility. A very similar backbone conformation is observed for the
loop structure in the ligand-free open conformation (PDB i.d. 1v4t),
with only minor differences in the phi and psi angles and in the
hydrogen-bonding network (Fig. 9B). Using the ﬂexible-backbonemeth-
od the Eris algorithm predicts local changes in the loop structure includ-
ing side chain motions (E265, D267 and F269) and changes in thehydrogen-bonding network of the loop (Fig. 9C and D). Moreover, a
shortening of the L271–S280 α-helix is indicated. Direct simulation ap-
proaches have not been attempted to further predict the structural
changes associated with the mutations, including the interphase of the
homodimers observed for both mutant proteins.
4. Discussion
The current spectrum of GCK-MODYmutations consists of >600mu-
tations [17], and various mechanisms have been demonstrated/proposed
to explain how the mutations cause diabetes. Functional characterization
of recombinant enzymes in vitro has identiﬁed some mutant forms
(V62M, E70K, G72R, L165F, V203A, S263P, E265K, M298K, E300K and
K414E) with an apparent reduced thermal stability, as measured by
heat-inactivation of the GST-GK fusion proteins at 30–52.5 °C
[20,21,23,39–44]. This in vitro instability has been suggested to repre-
sent the molecular mechanism for the hyperglycemic phenotype either
alone or in combination with a reduced catalytic efﬁciency and/or a
‘dysregulation’ by the liver speciﬁc inhibitory protein GKRP or the activa-
tor protein PFK-2/FBPase-2 [7,17,21,22,25,45,46]. In the present study,we
have focused on two mutations (amino acid substitutions S263P and
G264S) previously described in one patient with GCK-MODY and one
with neonatal diabetes, respectively [21,27]. The G264S mutation has
later also been found to coseggregate with MODY diabetes in three fami-
lies (Christine Bellanné-Chantelot, personal communication). Bothmuta-
tions have been reported to result in recombinant enzymes with normal/
near‐normal steady-state kinetics [20,21,27,42], andnormal regulationby
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mutation is also reported to cause a thermal instability of the recombinant
GST-GK fusion protein [21,44], as well as a cellular instability [25].
4.1. Comparison of GST-GK and tag-free GK at 30 and 37 °C
Up to date multiple studies [22,28,37,47] comparing the functional
properties of GST-GK and the tag-free pancreatic enzyme have re-
vealed similar enzyme kinetic parameters for the two forms. By con-
trast, in terms of thermal stability, the GST fusion partner may have a
stabilizing effect on GK, which is indicated by our comparison of WT
and S263P mutant protein with regard to the apparent overall turn-
over rate (kcat) assayed at 30 and 37 °C, in the presence and absenceA B
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Fig. 7. Catalytic activity of WT, S263P and G264S enzymes in HEK293 cell extracts. (A)
Glucose-dependent GK activity in cytosolic fractions of stably transfected HEK293 cells,
prepared by mechanical shear forces. The activity was measured spectrophotometrically
at 30 °C at equal amounts of cellular GK (~100 μg of total protein), as determined by
SDS/PAGE (10%) and immunoblotting (anti-GK and anti-actin Ab) (B). (C) Kinetic param-
eters calculated from data in (A) by nonlinear regression analysis using the Hill equation.
Data represents the mean±SD of three independent experiments (n=3).of GST (Fig. 1, Table 1). A stabilizing effect of GST on the mutant pro-
tein is not surprising since WT hGK without the fusion partner has a
marginal thermal stability (apparent Tm ~41 °C in Fig. 8A) and a pro-
pensity to aggregate at Tp≥40 °C as measured by CD spectroscopy
[37]. Our data are consistent with GST being a transiently stabilizing
protein for hGK, and notably for its mutant proteins with a lower Tm
value than for the WT (Fig. 8B), as previously observed for the GST
fusion protein with the catalytic domain of the nuclear inclusion pro-
tease from tobacco etch virus (TEV) [48], an effect which may be
explained by dimerization of the GST fusion protein [49].Fig. 6. PAGE analysis of the native and denatured state of WT and mutant hGK forms
overexpressed in cells and as recombinant proteins. Stably transfected HEK293 cells (A and
B) and MIN6 cells (C and D) were metabolically labeled with [35S]Met/[35S]Cys for 30 min
and chased for 2 h. WT, S263P and G264S mutant proteins were afﬁnity isolated. After
high-speed centrifugation of the eluate, the cytosolic fractions from HEK293 (A) and MIN6
cells (C) were analyzed by native-PAGE electrophoresis, and the pellets from HEK293 (B)
and MIN6 cells (D) analyzed by SDS/PAGE (4–12%) and immunoblotting (anti-V5 Ab) after
denaturation (56 °C, 15 min). (E) Analysis of TritonX-100 soluble and TritonX-100 insoluble
(guanidine chloride soluble) forms of the G264S mutant protein. The post-nuclear superna-
tant fractionofMIN6cells, stably expressing theG264Smutant form,was centrifuged and the
recovered supernatant and pellet fractions treated with 1% (v/v) Triton X-100. Following
high-speed centrifugation, the supernatants were referred to as Triton X-100 soluble hGK
protein. The resulting pellets were solubilized by sonication in 5 M guanidine chloride and
high‐speed centrifuged (referred to as Triton X-100-insoluble (guanidine chloride-soluble)
GK protein). The pellet sampleswere diluted 10-fold to reduce the concentration of denatur-
ant, prior to denaturation and analysis by SDS/PAGE (4–12%) and immunoblotting (anti-V5
Ab). (F) Densitometric quantiﬁcation of immunoreactive proteins in the supernatant (black
columns) and the pellet fractions (white columns) in E demonstratedmore TritonX-100 sol-
uble (supernatant>pellet) compared to Triton X-100 insoluble (guanidine chloride soluble)
G264S protein (n=3). For comparison, 10 μg of cleaved recombinant WT hGK and mutant
proteins were denatured and subjected to SDS/PAGE (4–12%) analyses and Coomassie blue
staining (G), and to native-PAGE (Novex 3–12% Bis-Tris Gel) analyses by running at 150 V
for 2 h in dark blue cathode buffers followed by Coomassie blue staining (H) and by immu-
noblotting (anti-V5 Ab) (I). Asterisk indicates dimeric forms. Monomeric and dimeric forms
were quantitated by densitometric analysis (for numbers see main text) and represent the
average of 3 (A–D) and 4 (H and I) experiments.
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Fig. 8. Thermal unfolding of WT and G264S hGK. The thermal unfolding proﬁle ofWT (A)
andG264S (B) at a concentration of 10 μM in the absence of Glcwas obtained by following
the change in ellipticity at 222 nm at a constant heating rate of 40 °C h−1. From the ﬁrst
derivative of the smoothed denaturation curve, apparent transition temperatures of
~40.8 °C (A) and ~35.5 °C (B) were determined for theWT and G264S hGK, respectively.
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mutant proteins
While it is established that a complex network of mechanisms is in-
volved in the regulation of GK catalytic activity in pancreatic β‐cells and
hepatocytes, relatively little is known regarding the cellular protein qual-
ity control (PQC) machinery involved in the recognition and targeted
degradation of GK and its many diabetes-associated mutant forms [17].
When stably expressed in HEK293 cells and insulin-secreting MIN6
β-cells, both mutant proteins (~53 kDa) revealed an increased rate of
degradation (Fig. 3) with monophasic decay curves and reduced appar-
ent half-lives, most pronounced for S263P (Fig. 4C and D). Whether the
increased rate of degradation of the mutants is compensated by an in-
creased level of their cellular mRNA expression was not investigated
here, but has not been found to be the case in otherGCK instabilitymuta-
tions [24,50]. By contrast, WT hGK revealed a biphasic decay curve
(Fig. 4A and B) in which the second and longest apparent half-life
(~13 h) corresponds well with the value (12.7 h) previously estimated
for rat GK (rGK) in rat liver hepatocytes [51], where the enzyme was
considered to be non-selectively sequestered and degraded by the
autophagosomal–lysosomal pathway. In our study, when the lysosomal
proteolytic activity was inhibited by leupeptin, the recovery of cellular
GK proteins (~53 kDa) increased (Fig. 5C and D). Our data indicate that
pancreatic hGK is also partly cleared by autophagy in both HEK293 and
MIN6 cells, possibly due to a preference for targeting and degradation
of oligomeric/aggregated mutant forms [52]. For both mutant proteins,aggregates were observed (G264S>S263P; G264S aggregates were
Triton X-100-insoluble (guanidine chloride soluble)) in HEK293 and
MIN6 cells, in both the cytosolic fraction and a subcellular fraction
enriched in lysosomes and mitochondria (Fig. 6). Previously, we have
demonstrated that WT pancreatic and liver hGK are covalently modiﬁed
by ubiquitination, serving as a signal for the degradation by the
ubiquitin–proteasome system (UPS) [12]. Here, when the proteasomal
proteolytic activity was blocked by the inhibitor MG132, the recovery
of the two misfolded mutant proteins slightly increased, both in the in
vitro coupled transcription/translation (RRL) system (Fig. 2D) and
when stably expressed in HEK293 or MIN6 cells (Fig. 5A and B).
4.3. In cellulo dimerization of S263P and G264S mutant proteins
Whereas the tag-free recombinant forms of E. coli expressed S263P
and G264S revealed a single monomeric (~50 kDa) band on SDS/PAGE
(Fig. 6G), both mutant proteins demonstrated an additional band with
a relative mobility corresponding to homodimeric GK species on
native-PAGE (Fig. 6H and I), and conﬁrmed by MS analyses (data not
shown). Similar dimeric species were seen when stably expressed as
V5-His‐tagged proteins in cells (Fig. 6A–D). This observation requires
a further comment. In general, 3D domain swapping represents a
common oligomerization mechanism in which two or more
polypeptide chains exchange identical units, and when two monomers
are involved, homodimers are formed [53,54]. In search for local signal
that may cause swapping, attention has focused on loop regions which
adopt a different conformation in monomeric and domain swapped
forms [55]. Proline residues are frequently found in loop regions
involved in domain swapped dimer formation, representing the
thermodynamically most stable state [56]. The F260-L270 loop of
hGK may similarly promote domain swapping when S263 and
G264 are mutated to Pro and Ser, respectively. Our in silico analyses
predict conformational changes in the loop of both mutant forms
(Fig. 9C and D), forming a conformation that promotes the formation
of homodimers. A similar mechanism has previously been reported
for the dimerization of monomeric immunoglobulin-binding domain
B1 of streptococcal protein G (GB1) by a single-point mutation [57].
The resistance of the hGK mutant dimers to denaturation by SDS at
56 °C (Fig. 6B and D) suggests the formation of a metastable compact,
globular dimeric structure, as previously demonstrated for dimeric
diphtheria toxin [53] and dimeric cyanivirin-N [56]. Moreover, using
an ANS ﬂuorescence binding assay, it is demonstrated (Fig. S2) a reduc-
tion in solvent exposed hydrophobic clusters in the mutant vs. the WT
enzyme, possibly related to a reduced accessibility of the hydrophobic
residues in the F260-L270 loop structure of the mutant and dimeriza-
tion involving these residues. Considering the stabilizing effect of
E265 on the WT loop conformation (Fig. 9A and B), it is not surprising
that the GCK-MODY mutant E265K has been reported to be very ther-
molabile, even as GST-GK fusion protein, while the mutation barely af-
fected the protein catalytic efﬁciency at 30 °C [41]. That formation of
dimers/oligomers of S263P and G264S is observed most pronounced
when the mutants are expressed in cells (Fig. 6) may be related to the
stabilization of a conformationallymore “open”monomer bymolecular
chaperones and the frequently observed effect of high protein concen-
tration on protein self-association in the cellular environment. Thus,
macromolecular crowding inﬂuences the structure and function of pro-
teins under physiological conditions and promotes protein–protein
interactions [55,58–61]. It remains to be seen how protein self-
association inﬂuences GK catalytic properties, as well as its association
with previously reported subcellular localizations, including mitochon-
dria, insulin granula, microtubuli and nucleus [62–65].
4.4. Relevance for the study of GK aggregation and degradation
In summary, our study has revealed an unexpected structural role
of the F260-L270 loop of hGK and demonstrated that the GCK-MODY
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Fig. 9. The position of S263 and G264 in the 3D structure of (A) the Glc-bound closed conformation (PDB i.d. 1v4s) and (B) the ligand-free conformation (PDB i.d. 1v4t) of pancreatic hGK. The
Cα-atom trace of the 11‐residue loop structure (F260-L270) is shown in ribbon, with key residues in stickmodel (D262, S263, G264 and E265) and linemodel (F260, L266, F269 and L270). The
polypeptide chain folds back on itself and the 3D structure is stabilized by hydrogen bonds and hydrophobic interactions formed by a cluster of packed apolar sidechains. (C) and (D) In silico
predicted conformational changes of the loop structure in the S263P (C) and G264S (D) mutant proteins using the Eris algorithm. The ﬁgure was created using PyMol, version 1.1.
1714 M. Negahdar et al. / Biochimica et Biophysica Acta 1822 (2012) 1705–1715mutations S263P and G264S generate misfolded and conformationally
unstable monomeric proteins which result in (i) an increased sensitivi-
ty to limited proteolysis in vitro, (ii) an enhanced rate of degradation
when expressed in HEK293 cells and MIN6 cells (S263P>G264S), and
(iii) an increased propensity to self-associate and form homodimers/
higher oligomers and aggregates (G264S>S263P) in these cells. Our
data highlight the variety of molecular mechanisms leading to GCK-
MODY diabetes and underline the importance of a cell-biological
approach to fully characterize the mutant enzymes, since protein
destabilization/aggregation and degradation may contribute to the mo-
lecular cause behind other GCK-MODY mutations. The study also sug-
gests a possible new therapeutic approach, different from GK allosteric
activators, by prevention of self-association (conformational rescue) of
some mutant proteins using bioactive small molecules (chemical/phar-
maceutical chaperones).
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.07.005.
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